New treatments include biologics, such as anti-TNFα agents (including infliximab, adalimumab, certolizumab pegol and golimumab), anti-integrin agents (vedolizumab), anti-IL-12/23 p40 subunit agents (including ustekinumab, risankizumab, mirikizumab) and new targeted small molecules (including upadacitinib, ozanimod, filgotinib), which have revolutionized the treatment of IBD (5–7). The gene discussed is TNF; the disease is inflammatory bowel disease.